Skip to main
MAZE

MAZE Stock Forecast & Price Target

MAZE Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 43%
Buy 57%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Maze Therapeutics Inc. is advancing its clinical-stage pipeline with promising programs MZE829 and MZE782, which target chronic kidney disease with innovative, precision medicine approaches, enhancing its potential for accelerated regulatory approval based on strong Phase 2 and Phase 1 trial data. The company’s ability to demonstrate significant efficacy signals, such as a ≥30-35% reduction in broad AMKD for MZE829 and a robust pharmacodynamic profile for MZE782, positions it favorably in the competitive landscape of renal and cardiovascular diseases. Additionally, Maze’s comprehensive enrollment strategy and focus on leveraging genetic insights to expand its addressable market underscore its commercial attractiveness and long-term growth potential.

Bears say

Maze Therapeutics Inc. faces significant challenges related to its investigational drug, inaxaplin, which may inflate the perceived efficacy signals due to inherent risks associated with chronic kidney disease (CKD) and the complexities of patient treatment regimens. The company's pipeline, particularly focusing on MZE829 and MZE782, could encounter setbacks as low baseline proteinuria and substantial scarring in diabetic kidney disease (DKD) patients complicate treatment outcomes, leading to potential financial impacts. Furthermore, the evaluation of various surrogate endpoints suggests that any modest reductions in key biomarkers could result in significant downside risks and indicate systemic safety concerns potentially limiting the effectiveness and marketability of their therapies.

MAZE has been analyzed by 7 analysts, with a consensus rating of Buy. 43% of analysts recommend a Strong Buy, 57% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Maze Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Maze Therapeutics Inc (MAZE) Forecast

Analysts have given MAZE a Buy based on their latest research and market trends.

According to 7 analysts, MAZE has a Buy consensus rating as of Jan 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $41, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $41, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Maze Therapeutics Inc (MAZE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.